Difference between revisions of "Talk:US KS Kansas City Wilkins H"
From Bioblast
Beno Marija (talk | contribs) (Created page with "{{O2k-Network Lab}}") |
Beno Marija (talk | contribs) |
||
Line 1: | Line 1: | ||
{{O2k-Network Lab}} | {{O2k-Network Lab | ||
|institution=Hemenway at University of Kansas Medical Center, | |||
Department of Neurology, | |||
University of Kansas Alzheimer’s Disease Center | |||
|address=2106 Olathe Blvd Bldg 64 Room 1039 | |||
|area code=66109 | |||
|city=Kansas City | |||
|state=Kansas (KS) | |||
|country=USA | |||
|Contact=Wilkins Heather M, | |||
|Status=O2k 2019- | |||
}} |
Revision as of 09:55, 22 January 2020
Talk:US KS Kansas City Wilkins H
O2k-Network Lab | Hemenway at University of Kansas Medical Center,
Department of Neurology, University of Kansas Alzheimer’s Disease Center |
---|---|
Address | 2106 Olathe Blvd Bldg 64 Room 1039, 66109 |
City | Kansas City |
State/Prov | Kansas (KS) |
Country | USA |
Weblink | |
Contact | Wilkins Heather M |
Team | |
Team previous | |
Status | O2k 2019- |
Oroboros Events | |
Topics |
O2k-Publications
Published | Reference | |
---|---|---|
Taylor 2024 Pilot Feasibility Stud | 2024 | Taylor MK, Burns JM, Choi IY, Herda TJ, Lee P, Smith AN, Sullivan DK, Swerdlow RH, Wilkins HM (2024) Protocol for a single-arm, pilot trial of creatine monohydrate supplementation in patients with Alzheimer's disease. Pilot Feasibility Stud 10:42. https://doi.org/10.1186/s40814-024-01469-5 |
Tungtur 2021 Sci Rep | 2021 | Tungtur SK, Wilkins HM, Rogers RS, Badawi Y, Sage JM, Agbas A, Jawdat O, Barohn RJ, Swerdlow RH, Nishimune H (2021) Oxaloacetate treatment preserves motor function in SOD1G93A mice and normalizes select neuroinflammation-related parameters in the spinal cord. Sci Rep 11:11051. |
O2k-Abstracts
update please